Advanced Enzyme Technologies Ltd · NSE:ADVENZYMES
Advanced Enzyme Technologies — Q4 FY21 Earnings Presentation
18 slides from Advanced Enzyme Technologies's earnings presentation, Jul 1, 2021
Slide 1: Cover letter to BSE and NSE
May 31, 2021 BSE Limited National Stock Exchange of India Limited P. J. Towers, Exchange Plaza, Plot No. C/1, Dalal Street, G Block Bandra-Kurla Complex, Mumbai- 400 001 Bandra (E) Mumbai- 400 051 Scrip Code-540025 Trading Symbol-ADVENZYMES Dear Sir, Subject: Press Release and Earnings Presentation
Slide 2: Announces Financial Results for Fourth Quarter and Year ended March 2021
FOR IMMEDIATE RELEASE EARNINGS RELEASE Date: May 31, 2021 Advanced Enzyme Technologies Limited announces Financial Results for Fourth Quarter and Year ended March 2021 Mumbai, India: Saturday, May 29, 2021 – Advanced Enzyme Technologies Limited (Advanced Enzymes; NSE: ADVENZYMES; BSE: 540025), a lea
Slide 3: Operational Performance Review
OPERATIONAL PERFORMANCE REVIEW: Segmental Revenue Annual Review: (Amount in INR Mn.) FY21 FY20 Change (%) Human Nutrition 3,786 3,211 18 Animal Nutrition 475 536 -11 Bio-Processing 678 555 -1 Geographical Revenue Annual Review: (Amount in INR Mn.) FY21 FY20 Change (%) India 2,287 1,879 20 USA 2,092
Slide 4: About Advanced Enzyme Technologies Limited
About Advanced Enzyme Technologies Limited Advanced Enzyme Technologies Limited, incorporated in 1989, is a research driven company with global leadership in the manufacturing of enzymes and probiotics. We are committed to providing eco-safe solutions to a wide variety of industries like human healt
Slide 5: Earnings Presentation Q4FY21
Earnings Presentation Q4FY21
Slide 6: Disclaimer
Disclaimer This information may contain certain forward-looking statements/details in the current scenario, which is extremely dynamic and increasingly fraught with risks and uncertainties. Actual results, performances, achievements or sequence of events may be materially different from the views ex
Slide 7: Company Overview
Company Overview What are enzymes? Enzymes are natural protein molecules that act as catalysts within living cells, produced by all living organisms. Function as specialized catalysts and accelerate the pace of biochemical reactions. Advanced uses enzymes to Advanced Enzymes is a research driven com
Slide 8: A Rising Global Star
Advanced Enzyme Technologies Limited – A Rising Global Star Manufacturing Units – 9 R&D Units – 7 } India – 5 | USA – 1 | Germany –1 India – 7 I USA - 2 REVENUE (₹ mn) 1st 2nd 2nd 5,018 Indian enzyme company Highest market share in Listed integrated 3,431 India enzyme player globally FY 17 FY 21 EBI
Slide 9: Results Summary – Q4FY21 (Consolidated) Y-o-Y
Results Summary – Q4FY21 (Consolidated) Y-o-Y *Revenue (₹ mn) EBITDA (₹ mn) PAT (₹ mn) 1,332 549 327 338 487 1,103 Q4FY20 Q4FY21 Q4FY20 Q4FY21 Q4FY20 Q4FY21 Revenue Breakup ₹ in Million *YoY Growth Animal HC Human HC Bio Processing -24% Q4FY21 131 Q4FY21 925 Q4FY21 197 (1%) Q4FY20 Q4FY20 787 Q4FY20
Slide 10: Revenue Split – Q4FY21 vs. Q4FY20
Revenue Split – Q4FY21 vs. Q4FY20 Q4FY21 Q4FY20 Product Category-wise (%) Product Category-wise (%) 16% 17% 10% 12% 74% 71% Human HC Animal HC Bio-Processing Human HC Animal HC Bio-Processing Geographical Revenue Split (%) Geographical Revenue Split (%) 1% 4% 3% 7% 38% 44% 43% 43% 9% 8% Asia (ex- In
Slide 11: Results Summary – FY21 (Consolidated) Y-o-Y
Results Summary – FY21 (Consolidated) Y-o-Y *Revenue (₹ mn) EBITDA (₹ mn) PAT (₹ mn) 5,018 1,515 2,315 4,440 1,330 2,023 FY20 FY21 FY20 FY21 FY20 FY21 Revenue Breakup ₹ in Million *YoY Growth Animal HC Human HC Bio Processing 11% -24% FY21 475 FY21 3,786 1% FY21 (1%) 678 FY20 FY20 3,211 FY20 683 536
Slide 12: Revenue Split – FY21 vs. FY20
Revenue Split – FY21 vs. FY20 FY21 FY20 Product Category-wise (%) Product Category-wise (%) 14% 15% 9% 12% 77% 73% Human HC Animal HC Bio-Processing Human HC Animal HC Bio-Processing Geographical Revenue Split (%) Geographical Revenue Split (%) 2% 2% 4% 6% 42% 42% 46% 43% 6% 7% Asia (ex- India) Othe
Slide 13: Profit & Loss (Consolidated) – Q4FY21 & FY21
Profit & Loss (Consolidated) – Q4FY21 & FY21 ₹ in Million except per share data Q4FY21 Q3FY21 Q4FY20 Y-o-Y FY21 FY20 Particulars Y-o-Y (%) Audited Unaudited Audited (%) Audited Audited Income from Operations 1,332 1,377 1,103 21% 5,018 4,440 13% Expenses 867 778 682 27% 2,986 2,675 12% Profit from O
Slide 14: Balance Sheet (Consolidated) – FY21
Balance Sheet (Consolidated) – FY21 ₹ in Million FY21 FY20 Particulars Audited Audited Assets Property, plant and equipment 2,382 2,096 Capital work-in-progress 104 101 Intangible assets 725 592 Goodwill 2,901 2,941 Other non-current assets 253 251 Current assets 5,162 3,757 Assets held for sale 0 4
Slide 15: Strong Financial Performance
Strong Financial Performance – FY20 ₹ in Million Revenue from Operations EBIDTA & EBIDTA Margin (%) 46% 46% 43% 2,500 50% 5,018 4,440 45% 48% 4,196 42% 2,000 3,957 46% 3,431 1,500 44% 42% 1,000 40% 500 1,534 1,654 1,819 2,023 2,315 38% 0 36% FY 17 FY 18 FY 19 FY 20 FY 21 FY 17 FY 18 FY 19 FY 20 FY 2
Slide 16: Strong Financial Performance
Strong Financial Performance – FY20 Net Working Capital (Days) Net Worth (₹ mn) 119 120 9,699 116 8,397 6,788 5,591 108 4,640 105 FY 17 FY 18 FY 19 FY 20 FY 21 FY 17 FY 18 FY 19 FY 20 FY 21 ROE (%) & ROCE (%) Net Debt to Equity (x) 27.00% 27.00% 24.00% 22.80% 22.50% 0.1 19.00% 18.00% 19.00% 17.50% 1
Slide 17: Shareholder Information
Shareholder Information Top 5 Institutional Holders (As on 21st May 2021) Stock Data (As on 21st May 2021) Institutions OS (%) ORBIMED ASIA III MAURITIUS 12.09 Market Capitalization (₹) 53,518 mn HDFC AMC 4.88 Shares Outstanding 111.72 mn NALANDA INDIA EQUITY FUND 4.75 Free Float 44.62% UTI MF 1.65
Slide 18: Thank You
Thank You Advanced Enzymes 5th Floor, 'A' wing, Sun Magnetica LIC Service Road, Louiswadi Thane (W) 400 604, India Tel: +91-22-4170 3200 Fax: + 91-22-25835159
Advanced Enzyme Technologies — Q4 FY21 Earnings Presentation on 6ix